Product Specification
| Alternative Name: | Prostaglandin E2 |
| |
| Host: | Rabbit |
| |
| Immunogen: | Prostaglandin E2. |
| |
| Source: | Purified from rabbit serum. |
| |
| Species reactivity: | Species independent
|
| |
| Applications: | ELISA
Radioimmunoassay
|
| |
| Formulation: | Liquid. In phosphate buffer containing bovine gamma globulin and 0.1% sodium azide. |
| |
| Handling: | Avoid freeze/thaw cycles. |
| |
| Shipping: | Shipped on Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | Prostaglandin E2 (PGE2) is an extensively studied prostaglandin owing to its predominance in inflammation, cancer, atherosclerosis, autoimmune disease, and sepsis. Oxidation of arachidonic acid by prostaglandin synthases (COX-1 and COX-2) produces prostaglandin H2 (PGH2), which is further metabolized by PGE synthases into its major product, PGE2. PGE2 mediates autocrine and paracrine signaling by binding to G-protein coupled receptors (EP1, EP2, EP3, EP4) on the cell surface, functioning to modulate phospholipase C and adenylate cyclase activity. PGE2 has been of great interest as a therapeutic target, either by modulation of its synthesis by COX inhibitors (NSAIDS) or by modulation of its receptors by downregulation or binding antagonists. PGE2 production in a variety of tissues has been shown to modulate numerous physiological processes including natriuresis in the kidney, smooth muscle elasticity in the vasculature, and the inflammatory response to damaged tissues by monocytes and macrophages. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
Inhibition of lipopolysaccharide-induced prostaglandin E(2) production and inflammation by the Na(+)/H(+) exchanger inhibitors: F. Kamachi, et al.; J. Pharmacol. Exp. Ther.
321, 345 (2007),
Application(s): RIA using mouse culture supernatants,
Abstract;
Molecular Characterization of Canine Prostaglandin G/H Synthase-2 and Regulation in Prostatic Adenocarcinoma Cells in Vitro: D. Boutemmine, et al. ; Endocrinology
143, 1134 (2002),
Application(s): RIA using canine cell lysates,
Abstract;
Highly Unsaturated (n-3) Fatty Acids, but Not {alpha}-Linolenic, Conjugated Linoleic or {gamma}-Linolenic Acids, Reduce Tumorigenesis in ApcMin/+ Mice: B.H. Petrik, et al. ; J. Nutr.
130, 2434 (2000),
Application(s): RIA using mouse cell lysates,
Abstract;
Down-Regulation of Oxytocin-Induced Cyclooxygenase-2 and Prostaglandin F Synthase Expression by Interferon-{tau} in Bovine Endometrial Cells: C.W. Xiao, et al. ; Biol. Reprod.
60, 656 (1999),
Application(s): RIA using bovine cell lysates,
Abstract;
14,15-Epoxyeicosatrienoic acid inhibits prostaglandin E2 production in vascular smooth muscle cells: X. Fang, et al. ; Am. J. Physiol. Heart Circ. Physiol.
275, H2113 (1998),
Application(s): RIA using porcine cell lysates,
Abstract;
Related Products
